BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1085 related articles for article (PubMed ID: 25662344)

  • 21. Monitoring the John Cunningham virus throughout natalizumab treatment in multiple sclerosis patients.
    Domínguez-Mozo MI; García-Montojo M; Arias-Leal A; García-Martínez Á; Santiago JL; Casanova I; Galán V; Arroyo R; Fernández-Arquero M; Alvarez-Lafuente R
    Eur J Neurol; 2016 Jan; 23(1):182-9. PubMed ID: 26498276
    [TBL] [Abstract][Full Text] [Related]  

  • 22. JCPyV microRNA in plasma inversely correlates with JCPyV seropositivity among long-term natalizumab-treated relapsing-remitting multiple sclerosis patients.
    Basnyat P; Virtanen E; Elovaara I; Hagman S; Auvinen E
    J Neurovirol; 2017 Oct; 23(5):734-741. PubMed ID: 28831768
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Long-term safety evaluation of natalizumab for the treatment of multiple sclerosis.
    Clerico M; Artusi CA; Di Liberto A; Rolla S; Bardina V; Barbero P; De Mercanti SF; Durelli L
    Expert Opin Drug Saf; 2017 Aug; 16(8):963-972. PubMed ID: 28641055
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The clinical utility of JC virus antibody index measurements in the context of progressive multifocal leukoencephalopathy.
    Reuwer AQ; Heron M; van der Dussen D; Schneider-Hohendorf T; Murk JL
    Acta Neurol Scand; 2017 Nov; 136 Suppl 201():37-44. PubMed ID: 29068484
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Association of Progressive Multifocal Leukoencephalopathy Lesion Volume With JC Virus Polymerase Chain Reaction Results in Cerebrospinal Fluid of Natalizumab-Treated Patients With Multiple Sclerosis.
    Wijburg MT; Kleerekooper I; Lissenberg-Witte BI; de Vos M; Warnke C; Uitdehaag BMJ; Barkhof F; Killestein J; Wattjes MP
    JAMA Neurol; 2018 Jul; 75(7):827-833. PubMed ID: 29532061
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Asymptomatic progressive multifocal leukoencephalopathy during natalizumab therapy with treatment.
    Fabis-Pedrini MJ; Xu W; Burton J; Carroll WM; Kermode AG
    J Clin Neurosci; 2016 Mar; 25():145-7. PubMed ID: 26541323
    [TBL] [Abstract][Full Text] [Related]  

  • 27. PML risk stratification using anti-JCV antibody index and L-selectin.
    Schwab N; Schneider-Hohendorf T; Pignolet B; Spadaro M; Görlich D; Meinl I; Windhagen S; Tackenberg B; Breuer J; Cantó E; Kümpfel T; Hohlfeld R; Siffrin V; Luessi F; Posevitz-Fejfár A; Montalban X; Meuth SG; Zipp F; Gold R; Du Pasquier RA; Kleinschnitz C; Jacobi A; Comabella M; Bertolotto A; Brassat D; Wiendl H
    Mult Scler; 2016 Jul; 22(8):1048-60. PubMed ID: 26432858
    [TBL] [Abstract][Full Text] [Related]  

  • 28. JC polyomavirus expression and bell-shaped regulation of its SF2/ASF suppressor during the follow-up of multiple sclerosis patients treated with natalizumab.
    Uleri E; Ibba G; Piu C; Caocci M; Leoni S; Arru G; Serra C; Sechi G; Dolei A
    J Neurovirol; 2017 Apr; 23(2):226-238. PubMed ID: 27812788
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Application of serum natalizumab levels during plasma exchange in MS patients with progressive multifocal leukoencephalopathy.
    Vennegoor A; Rispens T; Van Oosten BW; Wattjes MP; Wondergem MJ; Teunissen CE; Van der Kleij D; Uitdehaag BM; Polman CH; Killestein J
    Mult Scler; 2015 Apr; 21(4):481-4. PubMed ID: 25078275
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Host cell virus entry mechanisms enhance anti-JCV-antibody switch in natalizumab-treated multiple sclerosis patients.
    Achiron A; Miron G; Zilkha-Falb R; Magalashvili D; Dolev M; Stern Y; Gurevich M
    J Neurovirol; 2016 Dec; 22(6):736-746. PubMed ID: 27170332
    [TBL] [Abstract][Full Text] [Related]  

  • 31. John Cunningham virus conversion in relation to natalizumab concentration in multiple sclerosis patients.
    van Kempen ZLE; Leurs CE; de Vries A; Vennegoor A; Rispens T; Wattjes MP; Killestein J
    Eur J Neurol; 2017 Sep; 24(9):1196-1199. PubMed ID: 28707781
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Improving risk-stratification of natalizumab-associated PML.
    Tugemann B; Berger JR
    Ann Clin Transl Neurol; 2021 Mar; 8(3):696-703. PubMed ID: 33539683
    [TBL] [Abstract][Full Text] [Related]  

  • 33. High-frequency MRI monitoring should be performed in natalizumab-treated MS patients with higher risk of PML - YES.
    Yap SM; McGuigan C
    Mult Scler; 2017 May; 23(6):765-767. PubMed ID: 28287039
    [No Abstract]   [Full Text] [Related]  

  • 34. Natalizumab-treated patients at high risk for PML persistently excrete JC polyomavirus.
    Werner MH; Huang D
    J Neurovirol; 2016 Dec; 22(6):871-875. PubMed ID: 27198748
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Natalizumab-associated progressive multifocal leukoencephalopathy is not preceded by elevated drug concentrations.
    van Kempen ZL; Leurs CE; Vennegoor A; Wattjes MP; Rispens T; Uitdehaag BM; Killestein J
    Mult Scler; 2017 Jun; 23(7):995-999. PubMed ID: 28112019
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Course of neuropsychological impairment during natalizumab-associated progressive multifocal leukoencephalopathy.
    Kinner M; Prehn C; Schneider R; Schroeder C; Kolb E; Gold R; Hoepner R; Chan A
    Eur J Neurol; 2021 Mar; 28(3):921-927. PubMed ID: 33085811
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Statistical analysis of PML incidences of natalizumab-treated patients from 2009 to 2016: outcomes after introduction of the Stratify JCV® DxSelect™ antibody assay.
    Campagnolo D; Dong Q; Lee L; Ho PR; Amarante D; Koendgen H
    J Neurovirol; 2016 Dec; 22(6):880-881. PubMed ID: 27730447
    [No Abstract]   [Full Text] [Related]  

  • 38. JC Virus-DNA Detection Is Associated with CD8 Effector Accumulation in Peripheral Blood of Patients with Multiple Sclerosis under Natalizumab Treatment, Independently from JC Virus Serostatus.
    Zingaropoli MA; Iannetta M; Pontecorvo S; Anzivino E; Prezioso C; Rodio DM; Morreale M; D'Abramo A; Oliva A; Lichtner M; Cortese A; Frontoni M; Pietropaolo V; Francia A; Mastroianni CM; Vullo V; Ciardi MR
    Biomed Res Int; 2018; 2018():5297980. PubMed ID: 29682547
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Changes to anti-JCV antibody levels in a Swedish national MS cohort.
    Warnke C; Ramanujam R; Plavina T; Bergström T; Goelz S; Subramanyam M; Kockum I; Rahbar A; Kieseier BC; Holmén C; Olsson T; Hillert J; Fogdell-Hahn A
    J Neurol Neurosurg Psychiatry; 2013 Nov; 84(11):1199-205. PubMed ID: 23463870
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Assessment of JC virus DNA in blood and urine from natalizumab-treated patients.
    Rudick RA; O'Connor PW; Polman CH; Goodman AD; Ray SS; Griffith NM; Jurgensen SA; Gorelik L; Forrestal F; Sandrock AW; Goelz SE
    Ann Neurol; 2010 Sep; 68(3):304-10. PubMed ID: 20737514
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 55.